What is TWST's current stock price?

TWST (Twist Bioscience Corporation) is currently trading at $63.61 with a market cap of $3.96B.

What sector is Twist Bioscience Corporation in?

Twist Bioscience Corporation (TWST) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

Is TWST a good stock to buy?

Analysts have a Buy consensus on TWST with a price target of $64.40. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TWST Twist Bioscience Corporation

Healthcare

$63.61+0.00%OpenMarket Cap: $3.96B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.21

P/S

9.21

EV/EBITDA

-64.32

DCF Value

$-61.29

FCF Yield

-2.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.1%

Operating Margin

-33.9%

Net Margin

-19.8%

ROE

-17.5%

ROA

-12.0%

ROIC

-24.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$110.7M	$-44.0M	$—
Q1 null	$103.7M	$-30.5M	$—
Q4 null	$99.0M	$-27.1M	$—
FY null	$376.6M	$-77.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$64.40

Target (Median)

$65.00

Target Range

$52.00 - $80.00

1 Strong Buy8 Buy2 Hold0 Sell0 Strong Sell

Leerink PartnersOutperform

2026-05-05

BarclaysOverweight

2026-05-05

BairdOutperform

2026-05-05

GuggenheimBuy

2026-05-05

Evercore ISI GroupOutperform

2026-04-06

Trading Activity

Insider Trades

View All

JOHANNESSEN JANdirector

SellThu May 14

JOHANNESSEN JANdirector

SellThu May 14

WERNER ROBERT F.officer: Chief Accounting Officer

SellTue May 12

WERNER ROBERT F.officer: Chief Accounting Officer

SellWed May 06

Leproust Emily M.director, officer: Chief Executive Officer

SellWed May 06

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

2.23

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Peers

BGM